Efficacy of 3-day versus 5-day antibiotic therapy for clinically diagnosed nonsevere pneumonia in children from developing countries

European Journal of Emergency Medicine

Volumn 18, Issue 5, 2011, Pages 244-250

  Sutijono, Darrell ^a   Hom, Jeffrey ^b   Zehtabchi, Shahriar ^c  

^a KAISER PERMANENTE   (United States)

^b NEW YORK UNIVERSITY   (United States)

^c SUNY DOWNSTATE MEDICAL CENTER   (United States)

Author keywords

Antibiotics; developing countries; pediatric; pneumonia

Indexed keywords

AMOXICILLIN; AMPICILLIN; ANTIBIOTIC AGENT; AZITHROMYCIN; CLARITHROMYCIN; COTRIMOXAZOLE; ERYTHROMYCIN; MACROLIDE; PENICILLIN G;

ANTIBIOTIC THERAPY; CHILDHOOD DISEASE; DEVELOPING COUNTRY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; HUMAN; OUTCOMES RESEARCH; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE RISK; REVIEW; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT FAILURE; UNSPECIFIED SIDE EFFECT;

ANTI-BACTERIAL AGENTS; CHILD, PRESCHOOL; DEVELOPING COUNTRIES; DRUG ADMINISTRATION SCHEDULE; HEALTH SERVICES ACCESSIBILITY; HUMANS; INFANT; INFANT WELFARE; OUTPATIENTS; PNEUMONIA, BACTERIAL; TIME FACTORS; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 80052463087     PISSN: 09699546     EISSN: 14735695     Source Type: Journal    
DOI: 10.1097/MEJ.0b013e328344fd90     Document Type: Review

References (24)

1. Rudan I, Boschi-Pinto C, Biloglav Z, Mulholland K, Campbell H. Epidemiology and etiology of childhood pneumonia. Bull World Health Organ 2008; 86:408-416. (Pubitemid 351694322)
2. World Health Organization. Technicalbases for the WHO recommendations on the management of pneumonia in children at first-level health facilities. WHO/ARI/91.20. Geneva: World Health Organization; 1991.
3. Mc Intosh K. Community-acquired pneumonia in children. N Engl J Med 2002; 346:427-437.
4. Grant GB, Campbell H, Dowell SF, Graham SM, Klugman KP, Mulholland EK, et al. Recommendations for treatment of childhood non-severe pneumonia. Lancet 2009; 9:185-196.
5. World Health Organization. Antibiotics in the treatment ofacute respiratory infections inyoung children. WHO/ARI/90.10. Geneva: World Health Organization; 1990.
6. Reyes H, Guiscafré H, Muñoz O, Perez-Cuevas R, Martinez H, Gutierréz G. Antibiotic noncompliance and waste in upper respiratory infections and acute diarrhea. J Clin Epidemiol1997; 50:1297-1304. (Pubitemid 27501066)
7. Hoppe JE, Blumenstock G, Grotz W, Selbmann HK. Compliance of German pediatric patients with oral antibiotic therapy: results of a nationwide survey. Pediatr Infect Dis J 1999; 18:1085-1091.
8. Kardas P. Patient compliance with antibiotic treatment for respiratory tract infections. JAntimicrob Chemother 2002; 49:897-903. (Pubitemid 34692883)
9. Durbin WJ, Stille C. Pneumonia. Pediatr Rev 2008; 29:147-160.
10. Chambers HF. Protein synthesis inhibitors and miscellaneous antibacterial agents. In: Brunton LL, Lazo JS, Parker KL, editors. Goodman & Gilman's the pharmacologicalbasis oftherapeutics. 11th ed. New York: Mc Graw-Hill; 2006. pp. 1173-1202.
11. Wiley Inter Science. The Cochrane Library. Available at: http:// www3.interscience.wiley.com/cgi-bin/mrwhome/106568753/HOME. (Accessed May 2010).
12. Best Evidence Topics: Best BETS. Available at: http://bestbets.org. (Accessed May 2010).
13. Pakistan Multicentre Amoxycillin Short Course Therapy (MASCOT) Pneumonia Study Group. Clinical efficacy of 3 days versus 5 days of oral amoxicillin for treatment of childhood pneumonia: a multicentre double-blind trial. Lancet2002 ;360: 835-841.
14. Agarwal G, Awasthi S, Kabra SK, Kaul A, Singhi S, Walter SD; ISCAP Study Group. Three day versus five day treatment with amoxicillin for non-severe pneumonia in young children: a multicentre randomised controlled trial. BMJ 2004; 328:791.
15. Awasthi S, Agarwal G, Singh JV, Kabra SK, Pillai RM, Singhi S, et al.; ICMR-India Clen Pneumonia Project Group. Effectiveness of 3-Day amoxycillin vs. 5-Day co-trimoxazole in the treatment of non-severe pneumonia in children aged 2-59 months of age: a multi-centric open labeled trial. J Trop Pediatr 2008; 54:382-389.
16. Haider BA, Saeed MA, Bhutta ZA. Short-course versus long-course antibiotic therapy for non-severe community-acquired pneumonia in children aged 2-59 months. Cochrane Database Syst Rev. 2008;2:CD005976.
17. Kartasasmita C, Saha S; Short Course Cotrimoxazole Study Group. Three days versus five days oral cotrimoxazole for non-severe pneumonia. WHO/FCH/CAH/04.2. Geneva: World Health Organization; 2002.
18. Hazir T, Nisar YB, Qazi SA, Khan SF, Raza M, Zameer S, et al. Chest radiography in children aged 2-59 months diagnosed with non-severe pneumonia as defined by World Health Organization: descriptive multicentre study in Pakistan. BMJ 2006; 333:629.
19. Woods CR. Acute bacterial pneumonia in childhood in the current era. Pediatr Ann 2008; 37:694-702.
20. Madhi SA, Levine OS, Hajjeh R, Mansoor OD, Cherian T. Vaccines to prevent pneumonia and improve child survival. Bull World Health Organ 2008; 86:365-372. (Pubitemid 351694317)
21. O'Brien KL, Wolfson LJ, Watt JP, Henkle E, Deloria-Knoll M, Mc Call N, et al. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet 2009; 374:893-902.
22. Watt JP, Wolfson LJ, O'Brien KL, Henkle E, Deloria-Knoll M, Mc Call N, et al. Burden of disease caused by Haemophilus influenzae tybe b in children younger than 5 years: global estimates. Lancet 2009; 374:903-911.
23. Graham SM, English M, Hazir T, Enarson P, Duke T. Challenges to improving case management of childhood pneumonia at health facilities in resource-limited settings. Bull World Health Organ 2008; 86:349-355. (Pubitemid 351694315)
24. Wyer PC, Rowe BH, Guyatt GH, Cordell WH. Evidence-based emergency medicine. The clinician and the medical literature: when can we take a short-cut? Ann Emerg Med 2000; 36:149-155. (Pubitemid 30667022)